{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-039140","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2026-08-19T12:50:32+00:00","discovered_at":"2026-08-19T12:55:00.312021+00:00","generated_at":"2026-08-19T12:55:10.334078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INBS reports FY2026 revenue up 38% to $4.2M; gross margin expands to 48.63%","bullets":["FY2026 revenue $4.2M, up 38% YoY from $3.05M; gross profit $2.05M, up 64% YoY.","Gross margin 48.63%, up 778 bps from 40.85%; driven by Syrma Johari manufacturing transition.","Reader installed base 1,886 units (+22% YoY); consumable cartridges 106,500 (+35%); 502 active customers.","FDA 510(k) submission on track for H2 calendar 2026; all clinical data collection completed.","New strategic partnership with Bouygues UK for drug-testing rollout; eighth European patent granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-039140","json":"https://secwatch.observer/filing/0001493152-26-039140.json","markdown":"https://secwatch.observer/filing/0001493152-26-039140.md","text":"https://secwatch.observer/filing/0001493152-26-039140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/0001493152-26-039140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226039140/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-19T12:55:10.334078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}